|
AU2003225410A1
(en)
*
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
AU2004235396B2
(en)
|
2003-04-29 |
2010-11-25 |
Sarepta Therapeutics, Inc. |
Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
|
|
US20050222068A1
(en)
*
|
2003-10-23 |
2005-10-06 |
Mourich Dan V |
Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
|
|
WO2005072527A2
(en)
*
|
2004-01-23 |
2005-08-11 |
Avi Biopharma, Inc. |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US20050288246A1
(en)
|
2004-05-24 |
2005-12-29 |
Iversen Patrick L |
Peptide conjugated, inosine-substituted antisense oligomer compound and method
|
|
ES2627917T3
(es)
|
2004-06-28 |
2017-08-01 |
The University Of Western Australia |
Oligonucleótidos no codificantes para la inducción de la omisión exónica y métodos de uso de los mismos
|
|
US8129352B2
(en)
|
2004-09-16 |
2012-03-06 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating ssRNA viral infection
|
|
WO2006086667A2
(en)
|
2005-02-09 |
2006-08-17 |
Avi Bio Pharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
WO2007030691A2
(en)
*
|
2005-09-08 |
2007-03-15 |
Avi Biopharma, Inc. |
Antisense antiviral compound and method for treating picornavirus infection
|
|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
JP5173838B2
(ja)
|
2006-02-13 |
2013-04-03 |
アレシア・バイオセラピューティクス・インコーポレーテッド |
骨リモデリングのプロセスと関係があるポリヌクレオチドおよびポリペプチド配列
|
|
US8785407B2
(en)
*
|
2006-05-10 |
2014-07-22 |
Sarepta Therapeutics, Inc. |
Antisense antiviral agent and method for treating ssRNA viral infection
|
|
US20100016215A1
(en)
*
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
NZ584793A
(en)
|
2007-10-26 |
2012-05-25 |
Academisch Ziekenhuis Leiden |
Means and methods for counteracting muscle disorders
|
|
CA2710013A1
(en)
*
|
2007-12-28 |
2009-07-09 |
Avi Biopharma, Inc. |
Immunomodulatory agents and methods of use
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8231895B2
(en)
*
|
2008-05-22 |
2012-07-31 |
Universidade De Coimbra |
Targeted delivery to human diseases and disorders
|
|
US20110130346A1
(en)
*
|
2008-05-30 |
2011-06-02 |
Isis Innovation Limited |
Peptide conjugates for delvery of biologically active compounds
|
|
WO2009147368A1
(en)
*
|
2008-06-04 |
2009-12-10 |
Medical Research Council |
Peptides
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP3133160B1
(en)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for dmd
|
|
US8592386B2
(en)
*
|
2008-12-17 |
2013-11-26 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
CN102459595A
(zh)
|
2009-04-24 |
2012-05-16 |
普罗森那技术公司 |
用于治疗dmd的包含肌苷的寡核苷酸
|
|
US20110269665A1
(en)
|
2009-06-26 |
2011-11-03 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
HUE040445T2
(hu)
|
2009-11-12 |
2019-03-28 |
Univ Western Australia |
Antiszensz molekulák és eljárások betegségek kezelésére
|
|
AU2010319314C1
(en)
|
2009-11-13 |
2016-09-01 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
KR20120125455A
(ko)
*
|
2009-12-11 |
2012-11-15 |
광주과학기술원 |
세포내 타겟 결합용 바이포달 펩타이드 바인더
|
|
US9006415B2
(en)
*
|
2010-04-06 |
2015-04-14 |
Massachusetts Institute Of Technology |
Targeted delivery of nucleic acids
|
|
US9050373B2
(en)
*
|
2010-05-13 |
2015-06-09 |
The Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
|
|
KR101981705B1
(ko)
|
2010-05-28 |
2019-05-24 |
사렙타 쎄러퓨틱스, 인코퍼레이티드 |
변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
|
|
ES2756326T3
(es)
*
|
2010-07-19 |
2020-04-27 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
|
|
US8198429B2
(en)
|
2010-08-09 |
2012-06-12 |
Avi Biopharma, Inc. |
Antisense antiviral compounds and methods for treating a filovirus infection
|
|
US9161948B2
(en)
|
2011-05-05 |
2015-10-20 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
AU2011367230B2
(en)
*
|
2011-05-05 |
2017-08-10 |
Sarepta Therapeutics, Inc. |
Peptide oligonucleotide conjugates
|
|
WO2013030569A2
(en)
|
2011-08-30 |
2013-03-07 |
Michael John Gait |
Peptides
|
|
EP2750715B1
(en)
|
2011-08-30 |
2018-10-31 |
The Regents of The University of California |
Identification of small molecules that enhance therapeutic exon skipping
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
DK2581448T3
(en)
*
|
2011-10-13 |
2015-04-27 |
Ass Inst De Myologie |
Tricyclo-DNA phosphorothioate
|
|
WO2013086444A2
(en)
|
2011-12-08 |
2013-06-13 |
Sarepta Therapeutics, Inc. |
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
|
|
CA2862628C
(en)
*
|
2012-01-27 |
2021-08-24 |
Prosensa Technologies B.V. |
Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
|
|
EA201492120A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии atp2a2
|
|
US10174315B2
(en)
|
2012-05-16 |
2019-01-08 |
The General Hospital Corporation |
Compositions and methods for modulating hemoglobin gene family expression
|
|
CN104583402A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节mecp2表达的组合物和方法
|
|
JP2015523854A
(ja)
*
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
|
|
CN104540946A
(zh)
*
|
2012-05-16 |
2015-04-22 |
Rana医疗有限公司 |
用于调节utrn表达的组合物和方法
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
KR101329411B1
(ko)
*
|
2012-05-31 |
2013-11-14 |
주식회사 엘지생활건강 |
피부투과성 펩타이드
|
|
AU2013293062A1
(en)
|
2012-07-19 |
2014-07-24 |
Alethia Biotherapeutics Inc. |
Anti-Siglec-15 antibodies
|
|
WO2014028461A2
(en)
|
2012-08-13 |
2014-02-20 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
|
US10111962B2
(en)
*
|
2012-09-25 |
2018-10-30 |
Genzyme Corporation |
Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
|
|
CA2889044A1
(en)
|
2012-11-15 |
2014-05-22 |
Roche Innovation Center Copenhagen A/S |
Anti apob antisense conjugate compounds
|
|
CN103981147B
(zh)
|
2013-02-08 |
2017-11-10 |
中国科学院上海生命科学研究院 |
一种新的制备肝实质细胞的方法
|
|
US9217148B2
(en)
|
2013-03-14 |
2015-12-22 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
HK1220154A1
(zh)
|
2013-03-15 |
2017-04-28 |
Sarepta Therapeutics, Inc. |
改进的用於治疗肌营养不良的组合物
|
|
US10010562B2
(en)
|
2013-11-06 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
US9790495B2
(en)
|
2014-05-16 |
2017-10-17 |
Oregon State University |
Antisense antibacterial compounds and methods
|
|
CA2948568A1
(en)
|
2014-05-19 |
2015-11-26 |
David Greenberg |
Antisense antibacterial compounds and methods
|
|
TWI726844B
(zh)
|
2014-05-23 |
2021-05-11 |
美商健臻公司 |
胜肽載體上之多重寡核苷酸部分
|
|
AR100560A1
(es)
|
2014-05-23 |
2016-10-12 |
Genzyme Corp |
Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
|
|
WO2016108930A2
(en)
*
|
2014-12-31 |
2016-07-07 |
Geller Bruce L |
Antisense antibacterial compounds and methods
|
|
MA41795A
(fr)
*
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
US11020417B2
(en)
|
2015-06-04 |
2021-06-01 |
Sarepta Therapeutics, Inc |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
JP2018530560A
(ja)
*
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス， インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
|
AU2016379399B2
(en)
|
2015-12-23 |
2022-12-08 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
US11142764B2
(en)
*
|
2015-12-23 |
2021-10-12 |
Board Of Regents, The University Of Texas System |
Antisense antibacterial compounds and methods
|
|
KR102775461B1
(ko)
|
2016-04-01 |
2025-02-28 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩타이드 조성물 및 이의 용도
|
|
US11060089B2
(en)
|
2016-04-18 |
2021-07-13 |
Sarepta Therapeutics, Inc. |
Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
|
|
JP7042255B2
(ja)
|
2016-04-29 |
2022-03-25 |
サレプタ セラピューティクス， インコーポレイテッド |
ヒトｌｍｎａを標的にするオリゴヌクレオチド類縁体
|
|
ES3051834T3
(en)
|
2016-12-19 |
2025-12-30 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
NZ755416A
(en)
|
2016-12-19 |
2023-05-26 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
PT4122497T
(pt)
|
2016-12-19 |
2024-06-12 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
|
US10800817B2
(en)
*
|
2016-12-19 |
2020-10-13 |
Morehouse School Of Medicine |
Compositions and methods for treating diseases by inhibiting exosome release
|
|
KR20240172236A
(ko)
|
2017-01-06 |
2024-12-09 |
어비디티 바이오사이언시스 인크. |
핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법
|
|
US20180207293A1
(en)
*
|
2017-01-25 |
2018-07-26 |
2C Tech Corp. |
Nanoparticles for sustained ophthalmic drug delivery and methods of use
|
|
WO2018150196A1
(en)
|
2017-02-17 |
2018-08-23 |
Oxford University Innovation Limited |
Cell penetrating peptides modified by glycosylation
|
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
|
EP3687519A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
WO2019079386A1
(en)
*
|
2017-10-17 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
CELL PENETRATION PEPTIDES FOR ANTISENSE ADMINISTRATION
|
|
EP3713575A4
(en)
|
2017-11-21 |
2021-08-25 |
Rgenix, Inc. |
POLYMORPHS AND THEIR USES
|
|
JP7013626B2
(ja)
*
|
2018-01-05 |
2022-02-01 |
国立医薬品食品衛生研究所長 |
細胞膜透過ペプチド、構築物、及び、カーゴ分子を細胞内に輸送する方法
|
|
WO2019165183A1
(en)
|
2018-02-22 |
2019-08-29 |
Entrada Therapeutics, Inc. |
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
|
|
WO2019217682A1
(en)
|
2018-05-09 |
2019-11-14 |
Ohio State Innovation Foundation |
Cyclic cell-penetrating peptides with one or more hydrophobic residues
|
|
EP4219717A3
(en)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
US12018087B2
(en)
|
2018-08-02 |
2024-06-25 |
Dyne Therapeutics, Inc. |
Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
|
|
CN112955154A
(zh)
*
|
2018-08-02 |
2021-06-11 |
达因疗法公司 |
肌肉靶向复合物及其用于治疗强直性肌营养不良的用途
|
|
US12370264B1
(en)
|
2018-08-02 |
2025-07-29 |
Dyne Therapeutics, Inc. |
Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
|
|
US12097263B2
(en)
|
2018-08-02 |
2024-09-24 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
|
|
GB201812972D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
GB201812980D0
(en)
|
2018-08-09 |
2018-09-26 |
Univ Oxford Innovation Ltd |
Cell-penetrating peptides
|
|
AU2019394177A1
(en)
|
2018-12-07 |
2021-06-10 |
Oxford University Innovation Limited |
Linkers
|
|
BR112021011018A2
(pt)
|
2018-12-13 |
2021-08-31 |
Sarepta Therapeutics, Inc. |
Conjugados de oligômero para exon skipping para distrofia muscular
|
|
GB201821269D0
(en)
|
2018-12-28 |
2019-02-13 |
Nippon Shinyaku Co Ltd |
Myostatin signal inhibitor
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
GB201911403D0
(en)
*
|
2019-08-09 |
2019-09-25 |
Univ Oxford Innovation Ltd |
Conjugate and uses thereof
|
|
KR102270700B1
(ko)
*
|
2019-11-01 |
2021-06-30 |
한국과학기술연구원 |
폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
|
|
JP7689964B2
(ja)
|
2019-12-13 |
2025-06-09 |
インスピルナ，インコーポレーテッド |
金属塩及びその使用
|
|
IL294271A
(en)
|
2019-12-26 |
2022-08-01 |
Nippon Shinyaku Co Ltd |
Antisense nucleic acid that induces skipping of exon 50
|
|
PE20230237A1
(es)
|
2020-02-28 |
2023-02-07 |
Nippon Shinyaku Co Ltd |
Acidos nucleicos antisentido que inducen la omision del exon 51
|
|
US11969475B2
(en)
|
2021-07-09 |
2024-04-30 |
Dyne Therapeutics, Inc. |
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
|
|
US11987795B2
(en)
|
2020-11-24 |
2024-05-21 |
The Broad Institute, Inc. |
Methods of modulating SLC7A11 pre-mRNA transcripts for diseases and conditions associated with expression of SLC7A11
|
|
US20240327831A1
(en)
|
2020-12-23 |
2024-10-03 |
Sarepta Therapeutics, Inc. |
Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
|
|
CA3211038A1
(en)
|
2021-02-12 |
2022-08-18 |
Oxford University Innovation Limited |
Cell-penetrating peptide conjugates and methods of their use
|
|
WO2022232478A1
(en)
|
2021-04-30 |
2022-11-03 |
Sarepta Therapeutics, Inc. |
Treatment methods for muscular dystrophy
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
JPWO2022270585A1
(enExample)
|
2021-06-23 |
2022-12-29 |
|
|
|
US20240316093A1
(en)
|
2021-07-08 |
2024-09-26 |
Nippon Shinyaku Co., Ltd. |
Nephrotoxicity reducing agent
|
|
TW202308664A
(zh)
|
2021-07-08 |
2023-03-01 |
日商日本新藥股份有限公司 |
腎毒性減輕劑
|
|
TW202317147A
(zh)
|
2021-07-08 |
2023-05-01 |
日商日本新藥股份有限公司 |
析出抑制劑
|
|
WO2023034515A2
(en)
*
|
2021-09-03 |
2023-03-09 |
Sarepta Therapeutics, Inc. |
Delivery of anitsense oligomers by mirror image peptides
|
|
EP4493693A1
(en)
|
2022-03-17 |
2025-01-22 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
|
IL316143A
(en)
|
2022-04-15 |
2024-12-01 |
Dyne Therapeutics Inc |
Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
|
|
US20250289851A1
(en)
|
2022-04-22 |
2025-09-18 |
Entrada Therapeutics, Inc. |
Cyclic peptides for delivering therapeutics
|
|
US20260151538A1
(en)
|
2022-10-26 |
2026-06-04 |
Ada Forsyth Institute, Inc. |
Differentiation and reprogramming of chondrocyte
|
|
EP4612292A1
(en)
|
2022-11-02 |
2025-09-10 |
Sarepta Therapeutics, Inc. |
Formulation of an antisense oligomer conjugate
|
|
WO2024129459A1
(en)
|
2022-12-16 |
2024-06-20 |
University Of Rochester |
Repairmen! of barrier dysfunction in esophagus
|
|
WO2025085868A2
(en)
|
2023-10-20 |
2025-04-24 |
Radiation Control Technologies, Inc. |
Cd47-targeting morpholinos
|
|
WO2026080471A2
(en)
|
2024-10-07 |
2026-04-16 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of trem conjugates and uses thereof
|